This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
5hjs
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Identification of LXRbeta selective agonists for the treatment of Alzheimer's Disease== | ==Identification of LXRbeta selective agonists for the treatment of Alzheimer's Disease== | ||
| - | <StructureSection load='5hjs' size='340' side='right' caption='[[5hjs]], [[Resolution|resolution]] 1.72Å' scene=''> | + | <StructureSection load='5hjs' size='340' side='right'caption='[[5hjs]], [[Resolution|resolution]] 1.72Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[5hjs]] is a 4 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[5hjs]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5HJS OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5HJS FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=668:2-CHLORO-4-{1-[(2R)-2-HYDROXY-3-METHYL-2-(TRIFLUOROMETHYL)BUTANOYL]-4,4-BIPIPERIDIN-1-YL}-N,N-DIMETHYLBENZAMIDE'>668</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.72Å</td></tr> |
| - | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=668:2-CHLORO-4-{1-[(2R)-2-HYDROXY-3-METHYL-2-(TRIFLUOROMETHYL)BUTANOYL]-4,4-BIPIPERIDIN-1-YL}-N,N-DIMETHYLBENZAMIDE'>668</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | |
| - | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5hjs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hjs OCA], [https://pdbe.org/5hjs PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5hjs RCSB], [https://www.ebi.ac.uk/pdbsum/5hjs PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5hjs ProSAT]</span></td></tr> | |
| - | + | ||
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | |
</table> | </table> | ||
| - | == Disease == | ||
| - | [[http://www.uniprot.org/uniprot/NCOA1_HUMAN NCOA1_HUMAN]] Note=A chromosomal aberration involving NCOA1 is a cause of rhabdomyosarcoma. Translocation t(2;2)(q35;p23) with PAX3 generates the NCOA1-PAX3 oncogene consisting of the N-terminus part of PAX3 and the C-terminus part of NCOA1. The fusion protein acts as a transcriptional activator. Rhabdomyosarcoma is the most common soft tissue carcinoma in childhood, representing 5-8% of all malignancies in children. | ||
== Function == | == Function == | ||
| - | [ | + | [https://www.uniprot.org/uniprot/NR1H3_HUMAN NR1H3_HUMAN] Orphan receptor. Interaction with RXR shifts RXR from its role as a silent DNA-binding partner to an active ligand-binding subunit in mediating retinoid responses through target genes defined by LXRES. LXRES are DR4-type response elements characterized by direct repeats of two similar hexanuclotide half-sites spaced by four nucleotides. Plays an important role in the regulation of cholesterol homeostasis, regulating cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8 (By similarity). |
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 23: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 5hjs" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5hjs" style="background-color:#fffaf0;"></div> | ||
| + | |||
| + | ==See Also== | ||
| + | *[[Liver X receptor|Liver X receptor]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| - | [[Category: | + | [[Category: Homo sapiens]] |
| - | [[Category: | + | [[Category: Large Structures]] |
| - | [[Category: Klein | + | [[Category: Klein D]] |
| - | [[Category: Parthasarathy | + | [[Category: Parthasarathy G]] |
| - | + | ||
| - | + | ||
| - | + | ||
Revision as of 07:39, 9 August 2023
Identification of LXRbeta selective agonists for the treatment of Alzheimer's Disease
| |||||||||||
